Naltrexone in chronic schizophrenia. Results of a clinical trial.
Naltrexone in chronic schizophrenia. Results of a clinical trial.
复制标题
纳曲酮治疗慢性精神分裂症。
DOI：
--
复制
发表时间：
1980
期刊：
影响因子：
--
通讯作者：
T. Ban
中科院分区：
文献类型：
--
作者：
M. Ragheb;S. Berney;T. Ban
一项为期4周的临床试验，包括1周的安慰剂洗脱期，评估了纳洛酮在“新入院”的、活跃的幻觉性慢性精神分裂症患者中的抗精神病活性。发现慢性纳洛酮给药对2例患者有益，对3例患者无价值。反应性患者与无反应者的不同之处在于，尽管有足够的抗精神病药物维持治疗和对病理性幻觉经历的适当反应，但仍存在幻觉。根据这些发现，纳洛酮反应性精神分裂症亚组的可能性被认为是。
A 4-week clinical trial, including a 1-week placebo washout period, assessed the antipsychotic activity of naltrexone in 'newly admitted', actively hallucinating, chronic schizophrenics. Chronic naltrexone administration was found to benefit 2 patients and to be of no value in 3 patients. Responsive patients differed from non-responders by the presence of hallucinations despite adequate neuroleptic maintenance therapy and an appropriate response to pathological hallucinatory experience. On the basis of these findings, the possibility of a naltrexone-responsive schizophrenic subgroup was considered.